Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting PCSK9 for breast cancer metastasis

BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

BioCentury | Jun 9, 2014
Clinical News

ANG1005: Phase II started

BioCentury | Oct 28, 2013
Clinical News

ANG1005: Additional Phase II data

BioCentury | Oct 28, 2013
Clinical News

ANG1005: Phase II started

BioCentury | Dec 10, 2012
Clinical News

GRN1005: Development discontinued

Items per page:
1 - 10 of 19